218 related articles for article (PubMed ID: 20400900)
1. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
Fuchs I; Spiel AO; Frossard M; Derhaschnig U; Riedmüller E; Jilma B
Crit Care Med; 2010 Jun; 38(6):1423-9. PubMed ID: 20400900
[TBL] [Abstract][Full Text] [Related]
2. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882
[TBL] [Abstract][Full Text] [Related]
3. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
[TBL] [Abstract][Full Text] [Related]
5. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
[TBL] [Abstract][Full Text] [Related]
6. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.
Homoncik M; Jilma B; Hergovich N; Stohlawetz P; Panzer S; Speiser W
Thromb Haemost; 2000 Feb; 83(2):316-21. PubMed ID: 10739392
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
9. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
[TBL] [Abstract][Full Text] [Related]
10. The effect of off-pump coronary artery bypass grafting on platelet activation in patients on aspirin therapy until surgery day.
Suwalski G; Suwalski P; Filipiak KJ; Postuła M; Majstrak F; Opolski G
Eur J Cardiothorac Surg; 2008 Aug; 34(2):365-9; discussion 369. PubMed ID: 18550381
[TBL] [Abstract][Full Text] [Related]
11. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy.
Poulsen TS; Mickley H; Korsholm L; Licht PB; Haghfelt T; Jørgensen B
Thromb Res; 2007; 120(2):161-72. PubMed ID: 17052745
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
Second Chinese Cardiac Study (CCS-2) Collaborative Group
J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
[TBL] [Abstract][Full Text] [Related]
16. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Małek ŁA; Spiewak M; Filipiak KJ; Grabowski M; Szpotańska M; Rosiak M; Główczyńska R; Imiela T; Huczek Z; Opolski G
Kardiol Pol; 2007 Jan; 65(1):40-5; discussion 46. PubMed ID: 17295159
[TBL] [Abstract][Full Text] [Related]
17. The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity.
Santos MT; Madrid I; Moscardo A; Latorre AM; Bonastre J; Ruano M; Valles J
Platelets; 2014; 25(4):268-73. PubMed ID: 23909754
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
